Monogenic Hyperinsulinemic Hypoglycemia Disorders

Monogenic Hyperinsulinemic Hypoglycemia Disorders

Monogenic hyperinsulinemic hypoglycemia (HI) disorders are a group of rare genetic conditions characterized by inappropriate and unregulated insulin secretion from pancreatic β-cells, leading to persistent or recurrent hypoglycemia. These disorders are the most common cause of persistent hypoglycemia in neonates and infants, but they can also present later in childhood or, rarely, in adulthood. Early recognition is critical because recurrent hypoglycemia can cause irreversible neurological damage.

Pathophysiology

Under normal physiological conditions, insulin secretion is tightly regulated by blood glucose levels. In hyperinsulinemic hypoglycemia, insulin is secreted despite low plasma glucose, suppressing hepatic glucose production and ketogenesis while increasing peripheral glucose uptake. As a result, affected individuals experience hypoglycemia with inappropriately high insulin levels, low free fatty acids, and low ketone bodies.

Monogenic forms of HI arise from mutations in genes involved in glucose sensing, insulin secretion, or β-cell metabolism. These mutations disrupt the normal regulatory pathways, leading to excessive insulin release.

Genetic Causes

The most common genes implicated in monogenic HI include ABCC8 and KCNJ11, which encode the SUR1 and Kir6.2 subunits of the ATP-sensitive potassium (K_ATP) channel in pancreatic β-cells. Loss-of-function mutations in these genes impair potassium channel activity, resulting in membrane depolarization, calcium influx, and continuous insulin secretion. These mutations can cause either diffuse disease affecting the entire pancreas or focal disease limited to a specific region.

Other important genes include:

• GLUD1: Activating mutations cause hyperinsulinism–hyperammonemia (HI/HA) syndrome. Increased activity of glutamate dehydrogenase enhances insulin secretion, especially after protein intake.

• GCK: Activating mutations in glucokinase lower the glucose threshold for insulin release, leading to hypoglycemia.

• HADH: Mutations impair fatty acid oxidation and indirectly increase insulin secretion.

• HNF4A and HNF1A: These transcription factor mutations may cause transient or persistent neonatal hypoglycemia and are also associated with maturity-onset diabetes of the young (MODY) later in life.

• SLC16A1: Causes exercise-induced hyperinsulinemic hypoglycemia due to inappropriate expression of monocarboxylate transporter 1 in β-cells.

Clinical Presentation

The clinical spectrum of monogenic HI is broad. Severe forms typically present in the neonatal period with symptoms such as jitteriness, lethargy, poor feeding, apnea, or seizures. Milder forms may present later with recurrent hypoglycemic episodes triggered by fasting, illness, exercise, or protein-rich meals. Laboratory findings during hypoglycemia include detectable or elevated insulin levels, suppressed ketones, and a positive glycemic response to glucagon.

Diagnosis

Diagnosis is based on biochemical evidence of inappropriate insulin secretion during hypoglycemia, followed by genetic testing to identify the underlying mutation. Imaging techniques such as 18F-DOPA PET scanning are particularly useful in distinguishing focal from diffuse disease in patients with K_ATP channel mutations, as this distinction has important therapeutic implications.

Management

The primary goal of treatment is to maintain normoglycemia and prevent neurological injury. Diazoxide, a K_ATP channel opener, is the first-line therapy for many forms of HI, but it is ineffective in patients with inactivating K_ATP channel mutations. Octreotide, a somatostatin analog, and continuous enteral feeding may be used in diazoxide-unresponsive cases. In focal disease, surgical resection of the affected pancreatic region can be curative, whereas diffuse disease may require near-total pancreatectomy, which carries a risk of diabetes and exocrine pancreatic insufficiency.

Conclusion

Monogenic hyperinsulinemic hypoglycemia disorders represent a heterogeneous group of genetic conditions with significant clinical consequences. Advances in molecular genetics have improved diagnostic accuracy and enabled more targeted therapies. Early diagnosis, appropriate genetic evaluation, and individualized management are essential to optimize outcomes and prevent long-term neurological complications.

.